Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 30, 2023
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2022, along with program updates.
Key Financial Metrics
This Form 8-K serves as a notification of a press release (Exhibit 99.1) containing the detailed financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It references a press release that includes program updates and financial results for the period ended December 31, 2022.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on March 30, 2023, containing program updates and financial results.
Legal Disclaimer: The information in Items 2.02, 7.01, and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 30, 2023) for specific revenue, net loss, and cash position figures.
- Verify the details of the "program updates" mentioned in the Regulation FD disclosure.
- Confirm the status of the company's emerging growth company designation.
- Check the trading status of common stock (REVB) and redeemable warrants (REVBW) on The Nasdaq Stock Market LLC.